GlaxoSmithKline (Treximet sumatriptan / naproxen sodium) Overview

  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • M&A

  • Financing Rounds
  • 1

GlaxoSmithKline (Treximet sumatriptan / naproxen sodium) General Information

Description

Medication manufactured for the treatment of migraines. The tablets are effective in reducing symptoms of migraines, such as nausea and sensitivity to light or sound.

Contact Information

Formerly Known As
Trexima
Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Corporate Office
  • OT
  • United States
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Vertical(s)
Corporate Office
  • OT
  • United States

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

GlaxoSmithKline (Treximet sumatriptan / naproxen sodium) Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore GlaxoSmithKline (Treximet sumatriptan / naproxen sodium)‘s full profile, request access.

Request a free trial

GlaxoSmithKline (Treximet sumatriptan / naproxen sodium) Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore GlaxoSmithKline (Treximet sumatriptan / naproxen sodium)‘s full profile, request access.

Request a free trial

GlaxoSmithKline (Treximet sumatriptan / naproxen sodium) FAQs

  • Where is GlaxoSmithKline (Treximet sumatriptan / naproxen sodium) headquartered?

    GlaxoSmithKline (Treximet sumatriptan / naproxen sodium) is headquartered in OT.

  • What industry is GlaxoSmithKline (Treximet sumatriptan / naproxen sodium) in?

    GlaxoSmithKline (Treximet sumatriptan / naproxen sodium)’s primary industry is Drug Discovery.

  • Is GlaxoSmithKline (Treximet sumatriptan / naproxen sodium) a private or public company?

    GlaxoSmithKline (Treximet sumatriptan / naproxen sodium) is a Private company.

  • What is the current valuation of GlaxoSmithKline (Treximet sumatriptan / naproxen sodium)?

    The current valuation of GlaxoSmithKline (Treximet sumatriptan / naproxen sodium) is .

  • What is GlaxoSmithKline (Treximet sumatriptan / naproxen sodium)’s current revenue?

    The current revenue for GlaxoSmithKline (Treximet sumatriptan / naproxen sodium) is .

  • Who are GlaxoSmithKline (Treximet sumatriptan / naproxen sodium)’s investors?

    GSK has invested in GlaxoSmithKline (Treximet sumatriptan / naproxen sodium).

  • When was GlaxoSmithKline (Treximet sumatriptan / naproxen sodium) acquired?

    GlaxoSmithKline (Treximet sumatriptan / naproxen sodium) was acquired on 20-Aug-2014.

  • Who acquired GlaxoSmithKline (Treximet sumatriptan / naproxen sodium)?

    GlaxoSmithKline (Treximet sumatriptan / naproxen sodium) was acquired by Pernix Therapeutical Holdings.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process